NCT02491463View on ClinicalTrials.gov

A Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' RSV Investigational Vaccine (ChAd155-RSV) (GSK3389245A) in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

July 23, 2015

Primary Completion Date

April 8, 2016

Study Completion Date

January 26, 2017

Conditions
Respiratory Synctial Virus Infections
Interventions
BIOLOGICAL

GSK3389245A_LD GROUP

2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm

BIOLOGICAL

GSK3389245A_HD GROUP

2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm

BIOLOGICAL

Bexsero

2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm

DRUG

Placebo

2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm

Trial Locations (1)

OX3 7LJ

GSK Investigational Site, Oxford

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02491463 - A Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' RSV Investigational Vaccine (ChAd155-RSV) (GSK3389245A) in Healthy Adults | Biotech Hunter | Biotech Hunter